tradingkey.logo
๎™

Johnson & Johnson

JNJ
205.785USD
+5.825+2.91%
์‹œ์žฅ ์šด์˜ ์‹œ๊ฐ„ย ๏ผˆET๏ผ‰์‹œ์„ธ๋Š” 15๋ถ„ ์ง€์—ฐ๋ฉ๋‹ˆ๋‹ค
495.16B์‹œ๊ฐ€์ด์•ก
19.72P/E TTM
๎™

Johnson & Johnson

205.785
+5.825+2.91%
TradingKey ์ฃผ์‹ ์ ์ˆ˜
๊ฑด๊ฐ•
๋ฐธ๋ฅ˜์—์ด์…˜
์˜ˆ์ƒ
๋ชจ๋ฉ˜ํ…€
๊ธฐ๊ด€ ํˆฌ์ž์ž ์ธ์ง€๋„
์œ„ํ—˜ ์š”์†Œ
์œ ์‚ฌ ์ข…๋ชฉ
TradingKey ์ฃผ์‹ ์ ์ˆ˜
๊ฑด๊ฐ•
๋ฐธ๋ฅ˜์—์ด์…˜
์˜ˆ์ƒ
๋ชจ๋ฉ˜ํ…€
๊ธฐ๊ด€ ํˆฌ์ž์ž ์ธ์ง€๋„
์œ„ํ—˜ ์š”์†Œ
์œ ์‚ฌ ์ข…๋ชฉ

TradingKey Johnson & Johnson ์ฃผ์‹ ์ ์ˆ˜

ํ†ตํ™”: USD ๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: 2025-12-09

์ฃผ์š” ์ธ์‚ฌ์ดํŠธ

Johnson & Johnson์˜ ํŽ€๋”๋ฉ˜ํ„ธ์€ ๋น„๊ต์  ๊ฑด์ „ํ•œ ์ƒํƒœ์ด๋ฉฐ, ์„ฑ์žฅ ์ž ์žฌ๋ ฅ์€ ๋†’์Šต๋‹ˆ๋‹ค.๊ธฐ์—…์˜ ๋ฐธ๋ฅ˜์—์ด์…˜์€ ์ ์ •ํ•˜๊ฒŒ ํ‰๊ฐ€๋œ ๊ฒƒ์œผ๋กœ ๊ฐ„์ฃผ๋˜๋ฉฐ, ์ œ์•ฝ ์‚ฐ์—… ๋‚ด ๋žญํ‚น์€ 28/159์œ„์ž…๋‹ˆ๋‹ค.๊ธฐ๊ด€ ๋ณด์œ  ๋น„์œจ์€ ๋งค์šฐ ๋†’์€.์ง€๋‚œ ํ•œ ๋‹ฌ ๋™์•ˆ ์—ฌ๋Ÿฌ ์• ๋„๋ฆฌ์ŠคํŠธ๊ฐ€ ํ•ด๋‹น ๊ธฐ์—…์„ ๋งค์ˆ˜(์œผ)๋กœ ํ‰๊ฐ€ํ–ˆ์œผ๋ฉฐ, ์ตœ๊ณ  ๋ชฉํ‘œ ๊ฐ€๊ฒฉ์€ 203.44์ž…๋‹ˆ๋‹ค.์ค‘๊ธฐ์ ์œผ๋กœ ์ฃผ๊ฐ€๋Š” ์ƒ์Šน ์ถ”์„ธ์ผ ๊ฒƒ์œผ๋กœ ์˜ˆ์ƒ๋ฉ๋‹ˆ๋‹ค.์ง€๋‚œ ํ•œ ๋‹ฌ๊ฐ„ ์ฃผ์‹ ์‹œ์žฅ์—์„œ ํ‰๋ฒ”ํ•œ ์„ฑ๊ณผ๋ฅผ ๊ฑฐ๋‘์—ˆ์ง€๋งŒ, ๊ธฐ์—…์˜ ํŽ€๋”๋ฉ˜ํ„ธ๊ณผ ๊ธฐ์ˆ ์  ์ง€ํ‘œ๋Š” ํƒ„ํƒ„ํ•ฉ๋‹ˆ๋‹ค.์ฃผ๊ฐ€๋Š” ์ง€์ง€์„ ๊ณผ ์ €ํ•ญ์„  ์‚ฌ์ด์—์„œ ํšก๋ณดํ•˜๊ณ  ์žˆ์œผ๋ฉฐ, ๋ฒ”์œ„ ๋งค๋งค ๊ธฐ๋ฐ˜์˜ ์Šค์œ™ ํŠธ๋ ˆ์ด๋”ฉ์— ์ ํ•ฉํ•œ ์ƒํ™ฉ์ž…๋‹ˆ๋‹ค.

Johnson & Johnson ์ ์ˆ˜๎˜ฐ๎˜ฐ

๊ด€๋ จ ์ •๋ณด

์‚ฐ์—… ์ˆœ์œ„
28 / 159
์ „์ฒด ์ˆœ์œ„
84 / 4583
์‚ฐ์—…
์ œ์•ฝ

์ €ํ•ญ์„  & ์ง€์ง€์„ 

๊ธฐ์—…์ด ์•„์ง ๊ด€๋ จ ๋ฐ์ดํ„ฐ๋ฅผ ๊ณต๊ฐœํ•˜์ง€ ์•Š์•˜์Šต๋‹ˆ๋‹ค.

๋ ˆ์ด๋” ์ฐจํŠธ

ํ˜„์žฌ ๊ฐ€๊ฒฉ
๊ณผ๊ฑฐ

๋ถ„์„๊ฐ€ ๋ชฉํ‘œ๊ฐ€

28 ๋ช…์˜ ๋ถ„์„๊ฐ€๋ฅผ ๊ธฐ์ค€์œผ๋กœ
๋งค์ˆ˜
ํ˜„์žฌ ๋“ฑ๊ธ‰
203.437
๋ชฉํ‘œ ๊ฐ€๊ฒฉ
+0.90%
์ƒ์Šน ์—ฌ๋ ฅ
๋ฉด์ฑ… ์กฐํ•ญ: ์• ๋„๋ฆฌ์ŠคํŠธ ํ‰๊ฐ€ ๋ฐ ๋ชฉํ‘œ ์ฃผ๊ฐ€๋Š” ์ •๋ณด ์ œ๊ณต์„ ์œ„ํ•œ ๋ชฉ์ ์œผ๋กœ LSEG์—์„œ ์ œ๊ณต๋˜๋ฉฐ, ํˆฌ์ž ์กฐ์–ธ์œผ๋กœ ๊ฐ„์ฃผ๋˜์ง€ ์•Š์Šต๋‹ˆ๋‹ค.

Johnson & Johnson ์ฃผ์š” ๋‚ด์šฉ

๊ฐ•์ ์œ„ํ—˜ ์š”์†Œ
Johnson & Johnson, through its subsidiaries, is engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company's primary focus is products related to human health and well-being. It operates through two segments: Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. Products in this segment are distributed directly to retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment includes a broad portfolio of products used in the orthopedic, surgery, interventional solutions, cardiovascular intervention, and vision fields. The MedTech segment also offers a commercially available intravascular lithotripsy (IVL) platform for coronary artery disease (CAD) and peripheral artery disease (PAD).
์—…๊ณ„ ๋ฆฌ๋”
ํšŒ์‚ฌ์˜ ๋งค์ถœ์€ ์—…๊ณ„ ์„ ๋‘๋ฅผ ๋‹ฌ๋ฆฌ๊ณ  ์žˆ์œผ๋ฉฐ, ์ตœ๊ทผ ์—ฐ๊ฐ„ ๋งค์ถœ์€ ์ด ๋ฏธํ™” 88.82B์— ๋‹ฌํ•ฉ๋‹ˆ๋‹ค.
๋†’์€ ๋ฐฐ๋‹น๊ธˆ
ํšŒ์‚ฌ๋Š” ๋†’์€ ๋ฐฐ๋‹น๊ธˆ์„ ์ง€๊ธ‰ํ•˜๋Š” ํšŒ์‚ฌ๋กœ, ์ตœ์‹  ๋ฐฐ๋‹น๊ธˆ ์ง€๊ธ‰ ๋น„์œจ์€ 84.05%์ž…๋‹ˆ๋‹ค.
์•ˆ์ •์ ์ธ ๋ฐฐ๋‹น๊ธˆ
ํšŒ์‚ฌ๋Š” ์ง€๋‚œ 5๋…„ ๋™์•ˆ ์ •๊ธฐ์ ์œผ๋กœ ๋ฐฐ๋‹น๊ธˆ์„ ์ง€๊ธ‰ํ•˜์˜€์œผ๋ฉฐ, ์ตœ์‹  ๋ฐฐ๋‹น๊ธˆ ์ง€๊ธ‰ ๋น„์œจ์€ 84.05%์ž…๋‹ˆ๋‹ค.
๊ณต์ •ํ•œ ๊ฐ€์น˜
ํšŒ์‚ฌ์˜ ์ตœ์‹  PE์€ 19.16๋กœ, ์ตœ๊ทผ 3๋…„ ๊ธฐ์ค€ ์ค‘๊ฐ„ ๋ฐฑ๋ถ„์œ„ ๋ฒ”์œ„์— ์†ํ•ฉ๋‹ˆ๋‹ค.
๊ธฐ๊ด€ ๋งค์ˆ˜
์ตœ์‹  ๊ธฐ๊ด€ ๋ณด์œ  ์ฃผ์‹ ์ˆ˜๋Š” 1.79B์ฃผ์ด๋ฉฐ, ์ „ ๋ถ„๊ธฐ ๋Œ€๋น„ 0.00% ์ฆ๊ฐ€ํ–ˆ์Šต๋‹ˆ๋‹ค.
CI Select Canadian Equity Fund๊ฐ€ ๋ณด์œ 
์Šคํƒ€ ํˆฌ์ž์ž CI Select Canadian Equity Fund์ด(๊ฐ€) ์ด ์ฃผ์‹ 59.18K์ฃผ๋ฅผ ๋ณด์œ ํ•˜๊ณ  ์žˆ์Šต๋‹ˆ๋‹ค.

์žฌ๋ฌด ๊ฑด์ „์„ฑ

ํ†ตํ™”: USD ๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: 2025-12-09

Johnson & Johnson์˜ ํ˜„์žฌ ์žฌ๋ฌด ์ ์ˆ˜๋Š” 7.47์ ์ด๋ฉฐ, ์ œ์•ฝ ์‚ฐ์—… ๋‚ด ๋žญํ‚น์€ 111/159์œ„์ž…๋‹ˆ๋‹ค. ๊ธฐ์—…์˜ ์žฌ๋ฌด ์ƒํƒœ๋Š” ์•ˆ์ •์ ์ธ ์ƒํƒœ์ด๋ฉฐ, ๊ธฐ์—…์˜ ์šด์˜ ํšจ์œจ์„ฑ์€ ํ‰๊ท ์ž…๋‹ˆ๋‹ค. ๊ธฐ์—…์˜ ์ตœ๊ทผ ๋ถ„๊ธฐ ๋งค์ถœ์€ 23.99B์ด๋ฉฐ, ์ด๋Š” ์ „๋…„ 6.77% ๋Œ€๋น„ ์ฆ๊ฐ€์— ํ•ด๋‹นํ•ฉ๋‹ˆ๋‹ค. ํ•œํŽธ, ์ˆœ์ด์ต์€ ์ „๋…„ 91.24% ๋Œ€๋น„ ์ฆ๊ฐ€์„(๋ฅผ) ๊ธฐ๋กํ–ˆ์Šต๋‹ˆ๋‹ค.

์ฃผ์‹ ์ ์ˆ˜

๊ด€๋ จ ์ •๋ณด

๊ณผ๊ฑฐ
7.47
๋ณ€๊ฒฝ
0
๎™ธ

์žฌ๋ฌด ์ •๋ณด

๎˜ญ7.96

๊ด€๋ จ ์ง€ํ‘œ

ํ˜„๊ธˆ ๋ฐ ํ˜„๊ธˆ์„ฑ ์ž์‚ฐ
์ด ์ž์‚ฐ
๋ถ€์ฑ„ ์ด๊ณ„
์ž์œ  ํ˜„๊ธˆ ํ๋ฆ„
๊ธฐ์—…์ด ์•„์ง ๊ด€๋ จ ๋ฐ์ดํ„ฐ๋ฅผ ๊ณต๊ฐœํ•˜์ง€ ์•Š์•˜์Šต๋‹ˆ๋‹ค.
๎™น

์ˆ˜์ต์˜ ์งˆ

๎˜ญ7.63
๎™น

์šด์˜ ํšจ์œจ์„ฑ

๎˜ญ7.57
๎™น

์„ฑ์žฅ ์ž ์žฌ๋ ฅ

๎˜ญ6.73
๎™น

์ฃผ์ฃผ ์ˆ˜์ต๋ฅ 

๎˜ญ7.46

Johnson & Johnson ๊ธฐ์—… ๊ฐ€์น˜ ํ‰๊ฐ€

ํ†ตํ™”: USD ๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: 2025-12-09

Johnson & Johnson์˜ ํ˜„์žฌ ๊ฐ€์น˜ํ‰๊ฐ€ ์ ์ˆ˜๋Š” 7.77์ ์ด๋ฉฐ, ์ œ์•ฝ ์‚ฐ์—… ๋‚ด ๋žญํ‚น์€ 48/159์œ„์ž…๋‹ˆ๋‹ค. ํ˜„์žฌ ์ฃผ๊ฐ€์ˆ˜์ต๋น„์œจ(P/E)์€ 19.16์ด๋ฉฐ, ์ตœ๊ทผ ๊ณ ์  34.92 ๋Œ€๋น„ 82.25% ๋‚ฎ๊ณ , ์ตœ๊ทผ ์ €์  9.47 ๋Œ€๋น„ 50.60% ๋†’์Šต๋‹ˆ๋‹ค.

์ฃผ์‹ ์ ์ˆ˜

๊ด€๋ จ ์ •๋ณด

๊ณผ๊ฑฐ
7.77
๋ณ€๊ฒฝ
0

๋ฐธ๋ฅ˜์—์ด์…˜

์ฃผ๊ฐ€์ˆ˜์ต๋น„์œจ
P/B
์ฃผ๊ฐ€๋งค์ถœ๋น„์œจ
์ฃผ๊ฐ€ํ˜„๊ธˆํ๋ฆ„๋น„์œจ
์‚ฐ์—… ์ˆœ์œ„ 28/159
๊ธฐ์—…์ด ์•„์ง ๊ด€๋ จ ๋ฐ์ดํ„ฐ๋ฅผ ๊ณต๊ฐœํ•˜์ง€ ์•Š์•˜์Šต๋‹ˆ๋‹ค.

์˜ˆ์ƒ

ํ†ตํ™”: USD ๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: 2025-12-09

Johnson & Johnson์˜ ํ˜„์žฌ ์ˆ˜์ต ์ „๋ง ์ ์ˆ˜๋Š” 7.50์ ์ด๋ฉฐ, ์ œ์•ฝ ์‚ฐ์—… ๋‚ด ๋žญํ‚น์€ 103/159์œ„์ž…๋‹ˆ๋‹ค. Johnson & Johnson์˜ ํ‰๊ท  ๋ชฉํ‘œ ์ฃผ๊ฐ€๋Š” 205.00์ด๋ฉฐ, ์ตœ๊ณ ๊ฐ€๋Š” 230.00, ์ตœ์ €๊ฐ€๋Š” 170.00์ž…๋‹ˆ๋‹ค.

์ฃผ์‹ ์ ์ˆ˜

๊ด€๋ จ ์ •๋ณด

๊ณผ๊ฑฐ
7.50
๋ณ€๊ฒฝ
0

๋ชฉํ‘œ๊ฐ€

๊ธฐ์—…์ด ์•„์ง ๊ด€๋ จ ๋ฐ์ดํ„ฐ๋ฅผ ๊ณต๊ฐœํ•˜์ง€ ์•Š์•˜์Šต๋‹ˆ๋‹ค.

์• ๋„๋ฆฌ์ŠคํŠธ ํ‰๊ฐ€

28 ๋ช…์˜ ๋ถ„์„๊ฐ€๋ฅผ ๊ธฐ์ค€์œผ๋กœ
๋งค์ˆ˜
ํ˜„์žฌ ๋“ฑ๊ธ‰
203.437
๋ชฉํ‘œ ๊ฐ€๊ฒฉ
+0.90%
์ƒ์Šน ์—ฌ๋ ฅ
๊ฐ•๋ ฅ ๋งค์ˆ˜
๋งค์ˆ˜
์œ ์ง€
๋งค๋„
๊ฐ•๋ ฅ ๋งค๋„

๋™์ข…์—…๊ณ„ ๋น„๊ต

171
์ด๊ณ„
6
์ค‘๊ฐ„
8
ํ‰๊ท 
ํšŒ์‚ฌ ์ด๋ฆ„
ํ‰๊ฐ€
๋ถ„์„๊ฐ€
Johnson & Johnson
JNJ
28
Biogen Inc
BIIB
36
Amgen Inc
AMGN
35
Vertex Pharmaceuticals Inc
VRTX
33
Eli Lilly and Co
LLY
33
AbbVie Inc
ABBV
32
1
2
3
...
34

์žฌ๋ฌด ์˜ˆ์ธก

EPS
์ˆ˜์ต
์ˆœ์ด์ต
EBIT
๊ธฐ์—…์ด ์•„์ง ๊ด€๋ จ ๋ฐ์ดํ„ฐ๋ฅผ ๊ณต๊ฐœํ•˜์ง€ ์•Š์•˜์Šต๋‹ˆ๋‹ค.

๋ฉด์ฑ… ์กฐํ•ญ: ์• ๋„๋ฆฌ์ŠคํŠธ ํ‰๊ฐ€ ๋ฐ ๋ชฉํ‘œ ์ฃผ๊ฐ€๋Š” ์ •๋ณด ์ œ๊ณต์„ ์œ„ํ•œ ๋ชฉ์ ์œผ๋กœ LSEG์—์„œ ์ œ๊ณต๋˜๋ฉฐ, ํˆฌ์ž ์กฐ์–ธ์œผ๋กœ ๊ฐ„์ฃผ๋˜์ง€ ์•Š์Šต๋‹ˆ๋‹ค.

๋ชจ๋ฉ˜ํ…€

ํ†ตํ™”: USD ๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: 2025-12-09

Johnson & Johnson์˜ ํ˜„์žฌ ๊ฐ€๊ฒฉ ๋ชจ๋ฉ˜ํ…€ ์ ์ˆ˜๋Š” 8.80์ ์ด๋ฉฐ, ์ œ์•ฝ ์‚ฐ์—… ๋‚ด ๋žญํ‚น์€ 43/159์œ„์ž…๋‹ˆ๋‹ค. ํ˜„์žฌ ์ฃผ๊ฐ€๋Š” ์ €ํ•ญ์„  208.83๊ณผ ์ง€์ง€์„  190.07 ์‚ฌ์ด์—์„œ ๊ฑฐ๋ž˜๋˜๊ณ  ์žˆ์–ด, ํšก๋ณด ๊ตฌ๊ฐ„์„ ํ™œ์šฉํ•˜๋Š” ์Šค์œ™ ํŠธ๋ ˆ์ด๋”ฉ์— ์ ํ•ฉํ•œ ํ๋ฆ„์„ ๋ณด์ด๊ณ  ์žˆ์Šต๋‹ˆ๋‹ค.

์ฃผ์‹ ์ ์ˆ˜

๊ด€๋ จ ์ •๋ณด

๊ณผ๊ฑฐ
9.22
๋ณ€๊ฒฝ
-0.42

์ €ํ•ญ์„  & ์ง€์ง€์„ 

๊ธฐ์—…์ด ์•„์ง ๊ด€๋ จ ๋ฐ์ดํ„ฐ๋ฅผ ๊ณต๊ฐœํ•˜์ง€ ์•Š์•˜์Šต๋‹ˆ๋‹ค.

์ง€ํ‘œ

๎˜ฐ
๎˜ฐ

์ง€ํ‘œ ๊ธฐ๋Šฅ์€ ๋‹ค์–‘ํ•œ ๊ธฐ๋ฒ• ์ง€ํ‘œ๋ฅผ ๊ธฐ๋ฐ˜์œผ๋กœ ์—ฌ๋Ÿฌ ์ข…๋ชฉ์— ๋Œ€ํ•œ ๊ฐ€์น˜์™€ ๋ฐฉํ–ฅ ๋ถ„์„์„ ์ œ๊ณตํ•˜๋ฉฐ, ๊ธฐ์ˆ ์  ์š”์•ฝ๋„ ํ•จ๊ป˜ ์ œ๊ณตํ•ฉ๋‹ˆ๋‹ค.

์ด ๊ธฐ๋Šฅ์—๋Š” ์ผ๋ฐ˜์ ์œผ๋กœ ์‚ฌ์šฉ๋˜๋Š” 9๊ฐ€์ง€ ๊ธฐ์ˆ ์  ์ง€ํ‘œ๊ฐ€ ํฌํ•จ๋ฉ๋‹ˆ๋‹ค: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX, MA. ๋˜ํ•œ ํ•„์š”์— ๋”ฐ๋ผ ์‹œ๊ฐ„ ํ”„๋ ˆ์ž„์„ ์กฐ์ •ํ•  ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค.

๊ธฐ์ˆ  ๋ถ„์„์€ ํˆฌ์ž ์ฐธ์กฐ์˜ ์ผ๋ถ€์ผ ๋ฟ์ด๋ฉฐ, ๋ฐฉํ–ฅ์„ ํ‰๊ฐ€ํ•˜๊ธฐ ์œ„ํ•ด ์ˆซ์ž ๊ฐ’์„ ์‚ฌ์šฉํ•˜๋Š” ๋ฐ์—๋Š” ์ ˆ๋Œ€์ ์ธ ๊ธฐ์ค€์ด ์—†์Šต๋‹ˆ๋‹ค. ๊ฒฐ๊ณผ๋Š” ์ฐธ์กฐ์šฉ์ผ ๋ฟ์ด๋ฉฐ, ์ง€ํ‘œ ๊ณ„์‚ฐ ๋ฐ ์š”์•ฝ์˜ ์ •ํ™•์„ฑ์— ๋Œ€ํ•ด์„œ๋Š” ์ฑ…์ž„์ง€์ง€ ์•Š์Šต๋‹ˆ๋‹ค.

์ง€ํ‘œ
๋งค๋„(2)
์ค‘๋ฆฝ(3)
๋งค์ˆ˜(0)
์ง€ํ‘œ
๊ฐ€์น˜
๋ฐฉํ–ฅ
MACD(12,26,9)
-1.818
์ค‘๋ฆฝ
RSI(14)
52.402
์ค‘๋ฆฝ
STOCH(KDJ)(9,3,3)
10.338
๋งค๋„
ATR(14)
3.036
์ €๋ณ€๋™์„ฑ
CCI(14)
-96.350
์ค‘๋ฆฝ
Williams %R
93.120
๊ณผ๋งค์ˆ˜
TRIX(12,20)
0.298
๋งค๋„
StochRSI(14)
0.000
๊ณผ๋งค์ˆ˜
์ด๋™ ํ‰๊ท 
๋งค๋„(0)
์ค‘๋ฆฝ(0)
๋งค์ˆ˜(6)
์ง€ํ‘œ
๊ฐ€์น˜
๋ฐฉํ–ฅ
MA5
202.264
๋งค์ˆ˜
MA10
204.323
๋งค์ˆ˜
MA20
201.887
๋งค์ˆ˜
MA50
194.297
๋งค์ˆ˜
MA100
184.414
๋งค์ˆ˜
MA200
170.652
๋งค์ˆ˜

๊ธฐ๊ด€ ํˆฌ์ž์ž ์ธ์ง€๋„

ํ†ตํ™”: USD ๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: 2025-12-09

Johnson & Johnson์˜ ํ˜„์žฌ ๊ธฐ๊ด€ ์ฃผ์‹ ๋ณด์œ  ์ ์ˆ˜๋Š” 7.00์ ์ด๋ฉฐ, ์ œ์•ฝ ์‚ฐ์—… ๋‚ด ๋žญํ‚น์€ 44/159์œ„์ž…๋‹ˆ๋‹ค. ์ตœ์‹  ๊ธฐ๊ด€ ์ฃผ์‹ ๋ณด์œ  ๋น„์œจ์€ 74.44%์ด๋ฉฐ, ์ด๋Š” ์ง€๋‚œ ๋ถ„๊ธฐ ์ฆ๊ฐ€ ๋Œ€๋น„ 0.74%์ž…๋‹ˆ๋‹ค. ์ตœ๋Œ€ ๊ธฐ๊ด€ ์ฃผ์ฃผ์ธ ๋” ๋ฑ…๊ฐ€๋“œ์€(๋Š”) ์ „์ฒด ๋ฐœํ–‰ ์ฃผ์‹์˜ 9.78%์— ํ•ด๋‹นํ•˜๋Š” ์ด 235.57M์ฃผ์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•˜๊ณ  ์žˆ์œผ๋ฉฐ, ๋ณด์œ  ์ง€๋ถ„์€ 0.98% ์ฆ๊ฐ€์ž…๋‹ˆ๋‹ค.

์ฃผ์‹ ์ ์ˆ˜

๊ด€๋ จ ์ •๋ณด

๊ณผ๊ฑฐ
7.00
๋ณ€๊ฒฝ
0

๊ธฐ๊ด€ ์ฃผ์‹ ๋ณด์œ 

๊ธฐ์—…์ด ์•„์ง ๊ด€๋ จ ๋ฐ์ดํ„ฐ๋ฅผ ๊ณต๊ฐœํ•˜์ง€ ์•Š์•˜์Šต๋‹ˆ๋‹ค.

์ฃผ์ฃผ ํ™œ๋™

์ด๋ฆ„
๋ณด์œ  ์ฃผ์‹
Chg %
The Vanguard Group, Inc.
Star Investors๎˜ฏ
236.03M
+1.31%
State Street Investment Management (US)
132.80M
-0.74%
BlackRock Institutional Trust Company, N.A.
129.76M
+0.48%
Geode Capital Management, L.L.C.
60.61M
+2.06%
JP Morgan Asset Management
36.71M
+4.13%
State Farm Insurance Companies
34.37M
--
Norges Bank Investment Management (NBIM)
31.93M
+5.18%
Wellington Management Company, LLP
24.88M
+9.85%
Morgan Stanley Smith Barney LLC
25.30M
+5.13%
BlackRock Asset Management Ireland Limited
19.85M
+0.75%
1
2

์œ„ํ—˜ ์š”์†Œ๎˜ฐ๎˜ฐ

ํ†ตํ™”: USD ๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: 2025-12-09

Johnson & Johnson์˜ ํ˜„์žฌ ๋ฆฌ์Šคํฌ ํ‰๊ฐ€ ์ ์ˆ˜๋Š” 9.95์ ์ด๋ฉฐ, ์ œ์•ฝ ์‚ฐ์—… ๋‚ด ๋žญํ‚น์€ 1/159์œ„์ž…๋‹ˆ๋‹ค. ๊ธฐ์—…์˜ ๋ฒ ํƒ€ ๊ฐ’์€ 0.36์ž…๋‹ˆ๋‹ค. ์ด๋Š” ํ•ด๋‹น ์ฃผ์‹์ด ์ƒ์Šน์žฅ์—์„œ๋Š” ์ง€์ˆ˜ ๋Œ€๋น„ ์ƒ๋Œ€์ ์œผ๋กœ ์ €์กฐํ•œ ์„ฑ๊ณผ๋ฅผ ๋‚ด์ง€๋งŒ, ํ•˜๋ฝ์žฅ์—์„œ๋Š” ๋” ์ž‘์€ ํญ์˜ ํ•˜๋ฝ์— ๊ทธ์น˜๋Š” ๊ฒฝํ–ฅ์ด ์žˆ์Œ์„ ๋‚˜ํƒ€๋ƒ…๋‹ˆ๋‹ค.

์ฃผ์‹ ์ ์ˆ˜

๊ด€๋ จ ์ •๋ณด

๊ณผ๊ฑฐ
9.95
๋ณ€๊ฒฝ
0
S&P 500 ์ง€์ˆ˜ ๋Œ€๋น„ ๋ฒ ํƒ€๊ฐ’
0.36
VaR
+1.55%
240์ผ ์ตœ๋Œ€ ๋‚™ํญ
+12.73%
240์ผ ๋ณ€๋™์„ฑ
+20.41%

๋Œ์•„๊ฐ€๊ธฐ

์ตœ๊ณ  ์ผ๊ฐ„ ์ˆ˜์ต๋ฅ 
60์ผ
+2.88%
120์ผ
+6.19%
5๋…„
+6.19%
์ตœ์ € ์ผ๊ฐ„ ์ˆ˜์ต๋ฅ 
60์ผ
-1.77%
120์ผ
-1.77%
5๋…„
-7.59%
์ƒคํ”„ ๋น„์œจ
60์ผ
+3.51
120์ผ
+3.61
5๋…„
+0.51

์œ„ํ—˜ ์š”์†Œ

์ตœ๋Œ€ ๋‚™ํญ
240์ผ
+12.73%
3๋…„
+18.58%
5๋…„
+23.63%
์ˆ˜์ต ๋Œ€๋น„ ๋‚™ํญ ๋น„์œจ
240์ผ
+2.96
3๋…„
+0.33
5๋…„
+0.22
์™œ๋„
240์ผ
-0.67
3๋…„
+0.01
5๋…„
+0.09

๋ณ€๋™์„ฑ

์‹คํ˜„ ๋ณ€๋™์„ฑ
240์ผ
+20.41%
5๋…„
+17.70%
ํ‘œ์ค€ํ™”๋œ ์ง„ํญ ๋ฒ”์œ„
240์ผ
+1.40%
5๋…„
+1.26%
ํ•˜๋ฐฉ ๋ฆฌ์Šคํฌ ์กฐ์ • ์ˆ˜์ต๋ฅ 
120์ผ
+761.98%
240์ผ
+761.98%
์ตœ๊ณ  ์ผ๊ฐ„ ์ƒ์Šน ๋ณ€๋™์„ฑ
60์ผ
+11.07%
์ตœ๊ณ  ์ผ๊ฐ„ ํ•˜๋ฝ ๋ณ€๋™์„ฑ
60์ผ
+10.44%

์œ ๋™์„ฑ

ํ‰๊ท  ํšŒ์ „์œจ
60์ผ
+0.35%
120์ผ
+0.37%
5๋…„
--
ํšŒ์ „์œจ ํŽธ์ฐจ
20์ผ
+7.54%
60์ผ
+7.26%
120์ผ
+14.42%

์œ ์‚ฌ ์ข…๋ชฉ
๎˜ฐ๎˜ฐ

์ œ์•ฝ
๎™
Johnson & Johnson
Johnson & Johnson
JNJ
7.99 /10
์ฃผ์‹ ์ ์ˆ˜
์žฌ๋ฌด ๊ฑด์ „์„ฑ
๋ฐธ๋ฅ˜์—์ด์…˜
์˜ˆ์ƒ
๋ชจ๋ฉ˜ํ…€
๊ธฐ๊ด€ ํˆฌ์ž์ž ์ธ์ง€๋„
์œ„ํ—˜ ์š”์†Œ
Jazz Pharmaceuticals PLC
Jazz Pharmaceuticals PLC
JAZZ
8.86 /10
์ฃผ์‹ ์ ์ˆ˜
์žฌ๋ฌด ๊ฑด์ „์„ฑ
๋ฐธ๋ฅ˜์—์ด์…˜
์˜ˆ์ƒ
๋ชจ๋ฉ˜ํ…€
๊ธฐ๊ด€ ํˆฌ์ž์ž ์ธ์ง€๋„
์œ„ํ—˜ ์š”์†Œ
Collegium Pharmaceutical Inc
Collegium Pharmaceutical Inc
COLL
8.60 /10
์ฃผ์‹ ์ ์ˆ˜
์žฌ๋ฌด ๊ฑด์ „์„ฑ
๋ฐธ๋ฅ˜์—์ด์…˜
์˜ˆ์ƒ
๋ชจ๋ฉ˜ํ…€
๊ธฐ๊ด€ ํˆฌ์ž์ž ์ธ์ง€๋„
์œ„ํ—˜ ์š”์†Œ
Biogen Inc
Biogen Inc
BIIB
8.58 /10
์ฃผ์‹ ์ ์ˆ˜
์žฌ๋ฌด ๊ฑด์ „์„ฑ
๋ฐธ๋ฅ˜์—์ด์…˜
์˜ˆ์ƒ
๋ชจ๋ฉ˜ํ…€
๊ธฐ๊ด€ ํˆฌ์ž์ž ์ธ์ง€๋„
์œ„ํ—˜ ์š”์†Œ
ADMA Biologics Inc
ADMA Biologics Inc
ADMA
8.54 /10
์ฃผ์‹ ์ ์ˆ˜
์žฌ๋ฌด ๊ฑด์ „์„ฑ
๋ฐธ๋ฅ˜์—์ด์…˜
์˜ˆ์ƒ
๋ชจ๋ฉ˜ํ…€
๊ธฐ๊ด€ ํˆฌ์ž์ž ์ธ์ง€๋„
์œ„ํ—˜ ์š”์†Œ
United Therapeutics Corp
United Therapeutics Corp
UTHR
8.51 /10
์ฃผ์‹ ์ ์ˆ˜
์žฌ๋ฌด ๊ฑด์ „์„ฑ
๋ฐธ๋ฅ˜์—์ด์…˜
์˜ˆ์ƒ
๋ชจ๋ฉ˜ํ…€
๊ธฐ๊ด€ ํˆฌ์ž์ž ์ธ์ง€๋„
์œ„ํ—˜ ์š”์†Œ
๋” ๋ณด๊ธฐ

์ž์ฃผ ๋ฌป๋Š” ์งˆ๋ฌธ

TradingKey๋Š” ์–ด๋–ค ๋ฐฉ์‹์œผ๋กœ Johnson & Johnson์˜ ์ฃผ์‹ ์ ์ˆ˜๋ฅผ ์ƒ์„ฑํ•˜๋‚˜์š”?

๎™Œ
TradingKey ์ฃผ์‹ ์ ์ˆ˜๋Š” 100๊ฐœ ์ด์ƒ์˜ ๊ธฐ์ดˆ ๋ฐ์ดํ„ฐ ํฌ์ธํŠธ์—์„œ ๋„์ถœ๋œ 34๊ฐœ์˜ ์ง€ํ‘œ๋ฅผ ๊ธฐ๋ฐ˜์œผ๋กœ Johnson & Johnson์— ๋Œ€ํ•œ ์ข…ํ•ฉ ํ‰๊ฐ€๋ฅผ ์ œ๊ณตํ•ฉ๋‹ˆ๋‹ค.
์ด ์ง€ํ‘œ๋“ค์€ ์žฌ๋ฌด ๊ฑด์ „์„ฑ, ํšŒ์‚ฌ ๊ฐœ์š”, ์ˆ˜์ต ์˜ˆ์ƒ, ๊ฐ€๊ฒฉ ๋ชจ๋ฉ˜ํ…€, ๊ธฐ๊ด€ ์‹ ๋ขฐ, ๋ฆฌ์Šคํฌ ํ‰๊ฐ€์˜ ์—ฌ์„ฏ ๊ฐ€์ง€ ํ•ต์‹ฌ ์ฐจ์›์œผ๋กœ ๋ถ„๋ฅ˜๋˜๋ฉฐ, ์ด๋“ค์€ ํ•จ๊ป˜ Johnson & Johnson์˜ ์„ฑ๊ณผ์™€ ์ „๋ง์— ๋Œ€ํ•œ ์ฒ ์ €ํ•œ ๋ถ„์„์„ ํˆฌ์ž์ž์—๊ฒŒ ์ œ์‹œํ•ฉ๋‹ˆ๋‹ค.

Johnson & Johnson์˜ ์žฌ๋ฌด ๊ฑด์ „์„ฑ ์ ์ˆ˜๋Š” ์–ด๋–ป๊ฒŒ ์ƒ์„ฑ๋˜๋‚˜์š”?

๎™Œ
Johnson & Johnson์˜ ์žฌ๋ฌด ๊ฑด์ „์„ฑ ์ ์ˆ˜๋ฅผ ์‚ฐ์ถœํ•˜๊ธฐ ์œ„ํ•ด์„œ๋Š” ์žฌ๋ฌด ํŽ€๋”๋ฉ˜ํ„ธ, ์ˆ˜์ต ํ’ˆ์งˆ, ์šด์˜ ํšจ์œจ์„ฑ, ์„ฑ์žฅ ์ž ์žฌ๋ ฅ, ์ฃผ์ฃผ ์ˆ˜์ต ๋“ฑ์˜ ํ•ต์‹ฌ ์ฐจ์›์„ ๊ธฐ๋ฐ˜์œผ๋กœ ๋‹ค์–‘ํ•œ ์ฃผ์š” ์žฌ๋ฌด ์ง€ํ‘œ๋ฅผ ๋ถ„์„ํ•ฉ๋‹ˆ๋‹ค.
์ด๋Ÿฌํ•œ ์ข…ํ•ฉ ๋ฐ์ดํ„ฐ๋ฅผ ํ†ตํ•ฉํ•˜์—ฌ ๋„์ถœ๋œ ์žฌ๋ฌด ๊ฑด์ „์„ฑ ์ ์ˆ˜๋Š” Johnson & Johnson์˜ ์ „๋ฐ˜์ ์ธ ์•ˆ์ •์„ฑ, ์šด์˜ ํšจ์œจ์„ฑ, ์„ฑ์žฅ ์ž ์žฌ๋ ฅ๋ฟ๋งŒ ์•„๋‹ˆ๋ผ ์ฃผ์ฃผ์—๊ฒŒ ์ „๋‹ฌ๋˜๋Š” ์ˆ˜์ต๋„ ๋ฐ˜์˜ํ•ฉ๋‹ˆ๋‹ค. ์ด ์ ์ˆ˜๋Š” ํˆฌ์ž์ž ๋ฐ ๊ธฐํƒ€ ์ดํ•ด๊ด€๊ณ„์ž๊ฐ€ ํ•ฉ๋ฆฌ์ ์ธ ์˜์‚ฌ๊ฒฐ์ •์„ ๋‚ด๋ฆด ์ˆ˜ ์žˆ๋„๋ก ์ง€์›ํ•˜๋ฉฐ, ์ ์ˆ˜๊ฐ€ ๋†’์„์ˆ˜๋ก Johnson & Johnson์˜ ์žฌ๋ฌด ๊ฑด์ „์„ฑ์ด ์šฐ์ˆ˜ํ•จ์„ ์˜๋ฏธํ•ฉ๋‹ˆ๋‹ค.

Johnson & Johnson์˜ ๊ธฐ์—… ๊ฐ€์น˜ ์ ์ˆ˜๋Š” ์–ด๋–ป๊ฒŒ ์ƒ์„ฑ๋˜๋‚˜์š”?

๎™Œ
Johnson & Johnson์˜ ๊ธฐ์—… ๊ฐ€์น˜ํ‰๊ฐ€ ์ ์ˆ˜๋ฅผ ์‚ฐ์ถœํ•˜๊ธฐ ์œ„ํ•ด์„œ๋Š” ์ฃผ๊ฐ€์ˆ˜์ต๋น„์œจ(P/E), ์ฃผ๊ฐ€์ˆœ์ž์‚ฐ๋น„์œจ(P/B), ์ฃผ๊ฐ€๋งค์ถœ๋น„์œจ(P/S), ์ฃผ๊ฐ€ํ˜„๊ธˆํ๋ฆ„๋น„์œจ(P/CF) ๋“ฑ ๋‹ค์–‘ํ•œ ํ•ต์‹ฌ ์žฌ๋ฌด ๋น„์œจ์„ ์‚ฌ์šฉํ•ฉ๋‹ˆ๋‹ค. ์ด๋Ÿฌํ•œ ์ˆ˜์น˜๋Š” Johnson & Johnson์˜ ์‹œ์žฅ ๊ฐ€์น˜๋ฅผ ์ˆ˜์ต, ์ž์‚ฐ, ๋งค์ถœ ๋ฐ ํ˜„๊ธˆ ํ๋ฆ„๊ณผ ๋น„๊ตํ•˜์—ฌ ๊ธฐ์—… ๊ฐ€์น˜๋ฅผ ํ‰๊ฐ€ํ•˜๊ธฐ ์œ„ํ•œ ํ•ต์‹ฌ ์ง€ํ‘œ ์—ญํ• ์„ ํ•ฉ๋‹ˆ๋‹ค.
์ด๋Ÿฌํ•œ ๋น„์œจ๋“ค์„ ์ข…ํ•ฉ์ ์œผ๋กœ ๋ถ„์„ํ•จ์œผ๋กœ์จ, ๊ฐ€์น˜ํ‰๊ฐ€ ์ ์ˆ˜๋Š” ์‹œ์žฅ์ด ํ˜„์žฌ Johnson & Johnson์˜ ๊ฐ€์น˜๋ฅผ ์–ด๋–ป๊ฒŒ ์ธ์‹ํ•˜๊ณ  ์žˆ๋Š”์ง€๋ฟ๋งŒ ์•„๋‹ˆ๋ผ ๋ฏธ๋ž˜ ์ˆ˜์ต์„ฑ ๋ฐ ์„ฑ์žฅ ๊ฐ€๋Šฅ์„ฑ๊นŒ์ง€ ๋ฐ˜์˜ํ•˜์—ฌ ๋ณด๋‹ค ํ˜„๋ช…ํ•˜๊ฒŒ ํˆฌ์ž ๊ฒฐ์ •์„ ๋‚ด๋ฆด ์ˆ˜ ์žˆ๋„๋ก ์ง€์›ํ•ฉ๋‹ˆ๋‹ค. ์ ์ˆ˜๊ฐ€ ๋†’์„์ˆ˜๋ก Johnson & Johnson์˜ ๊ณต์ •๊ฐ€์น˜์— ๊ฐ€๊น๋‹ค๋Š” ์ ์„ ์˜๋ฏธํ•ฉ๋‹ˆ๋‹ค.

Johnson & Johnson์˜ ์ˆ˜์ต ์˜ˆ์ƒ ์ ์ˆ˜๋Š” ์–ด๋–ป๊ฒŒ ์ƒ์„ฑ๋˜๋‚˜์š”?

๎™Œ
Johnson & Johnson์˜ ์ˆ˜์ต ์˜ˆ์ƒ ์ ์ˆ˜๋ฅผ ์‚ฐ์ถœํ•˜๊ธฐ ์œ„ํ•ด ๋ถ„์„๊ฐ€ ํ‰๊ฐ€, ์žฌ๋ฌด ์˜ˆ์ƒ, ์ง€์ง€์„  ๋ฐ ์ €ํ•ญ์„ , ๊ทธ๋ฆฌ๊ณ  ์—…๊ณ„ ๋น„๊ต์™€ ๊ฐ™์€ ๋‹ค์–‘ํ•œ ํ•ต์‹ฌ ์ง€ํ‘œ๋ฅผ ๊ณ ๋ คํ•ฉ๋‹ˆ๋‹ค:
ํ˜„์žฌ ๋“ฑ๊ธ‰๊ณผ ๋ชฉํ‘œ ๊ฐ€๊ฒฉ์€ ๋ถ„์„๊ฐ€์˜ ๊ธฐ๋Œ€๋ฅผ ์ง์ ‘ ๋ฐ˜์˜ํ•˜๋ฉฐ, ์ƒ์Šน ์—ฌ๋ ฅ์€ ํ•ด๋‹น ์ฃผ์‹์˜ ์„ฑ์žฅ ์ž ์žฌ๋ ฅ์— ๋Œ€ํ•œ ๋ถ„์„๊ฐ€๋“ค์˜ ๋ณด๊ธฐ๋ฅผ ๋‚˜ํƒ€๋ƒ…๋‹ˆ๋‹ค.
์ฃผ๋‹น์ˆœ์ด์ต(EPS), ์ˆ˜์ต, ์ˆœ์ด์ต, ์ด์ž ๋ฐ ์„ธ๊ธˆ ์ฐจ๊ฐ ์ „ ์ด์ต(EBIT)๊ณผ ๊ฐ™์€ ์žฌ๋ฌด ์ง€ํ‘œ๋Š” ์ˆ˜์ต์„ฑ์„ ํ‰๊ฐ€ํ•˜๋Š” ํ•ต์‹ฌ ์ฒ™๋„์ž…๋‹ˆ๋‹ค.
๋ชฉํ‘œ ๊ฐ€๊ฒฉ์˜ ๊ณ ๊ฐ€, ์ค‘๊ฐ„๊ฐ’, ์ €๊ฐ€ ๊ฐ€๊ฒฉ ๋ฒ”์œ„๋ฅผ ๋ถ„์„ํ•จ์œผ๋กœ์จ, ๊ฐ€๊ฒฉ ์ถ”์„ธ๋ฅผ ํŒŒ์•…ํ•˜๊ณ  ํ•ต์‹ฌ ์ง€์ง€์„  ๋ฐ ์ €ํ•ญ์„ ์„ ์‹๋ณ„ํ•  ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค.
์ด๋Ÿฌํ•œ ์ง€ํ‘œ๋ฅผ ๋™์ข… ์—…๊ณ„์™€ ๋น„๊ตํ•จ์œผ๋กœ์จ ์ฃผ์‹์˜ ์„ฑ๊ณผ์— ๋Œ€ํ•œ ๋งฅ๋ฝ์„ ์ œ๊ณตํ•˜๊ณ  ๋ณด๋‹ค ํ˜„์‹ค์ ์ธ ์˜ˆ์ƒ ์„ค์ •์— ๋„์›€์ด ๋ฉ๋‹ˆ๋‹ค.
์ด๋Ÿฌํ•œ ์š”์†Œ๋“ค์€ ํ†ตํ•ฉ๋˜์–ด ์ฃผ์‹์˜ ์˜ˆ์ƒ ์žฌ๋ฌด ์‹ค์ ๊ณผ ์„ฑ์žฅ ์ž ์žฌ๋ ฅ์„ ์ •ํ™•ํ•˜๊ฒŒ ๋ฐ˜์˜ํ•˜๋Š” ์ข…ํ•ฉ์ ์ธ ์ˆ˜์ต ์˜ˆ์ƒ ์ ์ˆ˜๋ฅผ ๊ตฌ์„ฑํ•ฉ๋‹ˆ๋‹ค. ์ ์ˆ˜๊ฐ€ ๋†’์„์ˆ˜๋ก ๋ถ„์„๊ฐ€๋Š” Johnson & Johnson์˜ ๋ฏธ๋ž˜ ์ „๋ง์„ ๋” ๋‚™๊ด€์ ์œผ๋กœ ๋ณด๊ณ  ์žˆ์Œ์„ ์‹œ์‚ฌํ•ฉ๋‹ˆ๋‹ค.

Johnson & Johnson์˜ ๊ฐ€๊ฒฉ ๋ชจ๋ฉ˜ํ…€ ์ ์ˆ˜๋Š” ์–ด๋–ป๊ฒŒ ์ƒ์„ฑ๋˜๋‚˜์š”?

๎™Œ
Johnson & Johnson์˜ ๊ฐ€๊ฒฉ ๋ชจ๋ฉ˜ํ…€ ์ ์ˆ˜๋ฅผ ์‚ฐ์ถœํ•˜๊ธฐ ์œ„ํ•ด์„œ๋Š” ์ง€์ง€์„  ๋ฐ ์ €ํ•ญ์„ ๊ณผ ๊ฑฐ๋ž˜๋Ÿ‰ ์ˆ˜์น˜๋ฅผ ํฌํ•จํ•œ ๋ชจ๋ฉ˜ํ…€ ์ง€ํ‘œ๋ฅผ ๋ถ„์„ํ•ฉ๋‹ˆ๋‹ค.
์ง€์ง€์„ ์€ ๋งค์ˆ˜ ์ˆ˜์š”๊ฐ€ ์ปค์„œ ๊ฐ€๊ฒฉ ํ•˜๋ฝ์„ ๋ฐฉ์–ดํ•  ์ˆ˜ ์žˆ๋Š” ๊ฐ€๊ฒฉ ์ˆ˜์ค€์„ ์˜๋ฏธํ•˜๋ฉฐ, ์ €ํ•ญ์„ ์€ ๋งค๋„ ์••๋ ฅ์ด ์ฃผ๊ฐ€ ์ƒ์Šน์„ ๋ฐฉํ•ดํ•  ์ˆ˜ ์žˆ๋Š” ๊ฐ€๊ฒฉ ์ˆ˜์ค€์„ ์˜๋ฏธํ•ฉ๋‹ˆ๋‹ค. ์ผ๋ฐ˜์ ์ธ ๊ฐ€๊ฒฉ ๊ฑฐ๋ž˜๋Ÿ‰๊ณผ ์ด ๊ฑฐ๋ž˜๋Ÿ‰์„ ํ•จ๊ป˜ ๋ถ„์„ํ•จ์œผ๋กœ์จ ์‹œ์žฅ์—์„œ์˜ ์ „๋ฐ˜์ ์ธ ํ™œ๋™์„ฑ๊ณผ ์œ ๋™์„ฑ์„ ํ‰๊ฐ€ํ•ฉ๋‹ˆ๋‹ค. ์ด๋Ÿฌํ•œ ์ง€ํ‘œ๋Š” ๊ฐ€๊ฒฉ ์ถ”์„ธ์™€ ์ž ์žฌ์ ์ธ ๋ณ€ํ™”๋ฅผ ์‹๋ณ„ํ•˜๋Š” ๋ฐ ๋„์›€์„ ์ฃผ์–ด ํ–ฅํ›„ ์ˆ˜์ต์„ ๋ณด๋‹ค ์ •ํ™•ํ•˜๊ฒŒ ์˜ˆ์ธกํ•  ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค.
์ด์™€ ๊ฐ™์€ ์ข…ํ•ฉ์ ์ธ ๋ถ„์„์€ ์‹œ์žฅ ์‹ฌ๋ฆฌ๋ฅผ ๋ฐ˜์˜ํ•˜๊ณ  Johnson & Johnson์˜ ๊ฐ€๊ฒฉ์— ๋Œ€ํ•œ ํ•ฉ๋ฆฌ์ ์ธ ์˜ˆ์ƒ์„ ๊ฐ€๋Šฅํ•˜๊ฒŒ ํ•ฉ๋‹ˆ๋‹ค. ์ ์ˆ˜๊ฐ€ ๋†’์„์ˆ˜๋ก Johnson & Johnson์˜ ๋‹จ๊ธฐ ๊ฐ€๊ฒฉ ์ถ”์„ธ๊ฐ€ ๋” ์•ˆ์ •์ ์ž„์„ ๋‚˜ํƒ€๋ƒ…๋‹ˆ๋‹ค.

Johnson & Johnson์˜ ๊ธฐ๊ด€ ์‹ ๋ขฐ ์ ์ˆ˜๋Š” ์–ด๋–ป๊ฒŒ ์ƒ์„ฑ๋˜๋‚˜์š”?

๎™Œ
Johnson & Johnson์˜ ๊ธฐ๊ด€ ์‹ ๋ขฐ๋„ ์ ์ˆ˜๋ฅผ ์‚ฐ์ถœํ•˜๊ธฐ ์œ„ํ•ด์„œ๋Š” ๊ธฐ๊ด€์ด ๋ณด์œ ํ•œ ์ฃผ์‹์˜ ๋น„์œจ๊ณผ ๋ณด์œ  ์ฃผ์‹ ์ˆ˜๋ฅผ ๋ถ„์„ํ•ฉ๋‹ˆ๋‹ค. ๊ธฐ๊ด€ ๋ณด์œ  ๋น„์œจ์ด ๋†’์„์ˆ˜๋ก ์ „๋ฌธ ํˆฌ์ž์ž๋“ค์˜ ์‹ ๋ขฐ๋„๊ฐ€ ๋†’๋‹ค๋Š” ์ ์„ ์˜๋ฏธํ•˜๋ฉฐ, Johnson & Johnson์˜ ์ž ์žฌ๋ ฅ์— ๋Œ€ํ•œ ๊ฐ•์„ธ ์‹ ํ˜ธ๋กœ ํ•ด์„๋ฉ๋‹ˆ๋‹ค. ๊ธฐ๊ด€ ํˆฌ์ž์ž๋Š” ์ผ๋ฐ˜์ ์œผ๋กœ ์ฒ ์ €ํ•œ ๋ถ„์„์„ ์ˆ˜ํ–‰ํ•œ ์ดํ›„ ํˆฌ์ž ๊ฒฐ์ •์„ ๋‚ด๋ฆฌ๋ฏ€๋กœ ๊ธฐ๊ด€ ๋ณด์œ  ์ฃผ์‹ ์ˆ˜๋ฅผ ๋ถ„์„ํ•˜๋ฉด ํ•ด๋‹น ์ฃผ์‹์— ๋Œ€ํ•œ ๊ธฐ๊ด€์˜ ์˜์ง€์™€ ํƒœ๋„๋ฅผ ๋” ๊นŠ์ด ์ดํ•ดํ•  ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค. ๊ธฐ๊ด€ ์‹ ๋ขฐ๋„๋ฅผ ์ดํ•ดํ•˜๋ฉด ์ˆ˜์ต ์˜ˆ์ƒ์„ ๋ณด๋‹ค ์ •๊ตํ•˜๊ฒŒ ๋‹ค๋“ฌ๊ณ , ๊ธฐ์—…์˜ ํ–ฅํ›„ ์„ฑ๊ณผ ๋ฐ ์‹œ์žฅ ์•ˆ์ •์„ฑ์— ๋Œ€ํ•ด ๋” ์‹ ๋ขฐํ•  ์ˆ˜ ์žˆ๋Š” ์‹œ๊ฐ์„ ์ œ๊ณตํ•ฉ๋‹ˆ๋‹ค. ์ ์ˆ˜๊ฐ€ ๋†’์„์ˆ˜๋ก Johnson & Johnson์— ๋Œ€ํ•œ ๊ธฐ๊ด€์˜ ์ง€์ง€๋„๊ฐ€ ๋” ๋†’๋‹ค๋Š” ๊ฒƒ์„ ์˜๋ฏธํ•ฉ๋‹ˆ๋‹ค.

Johnson & Johnson์˜ ๋ฆฌ์Šคํฌ ๊ด€๋ฆฌ ์ ์ˆ˜๋Š” ์–ด๋–ป๊ฒŒ ์ƒ์„ฑ๋˜๋‚˜์š”?

๎™Œ
Johnson & Johnson์˜ ๋ฆฌ์Šคํฌ ๊ด€๋ฆฌ ์ ์ˆ˜๋ฅผ ํ‰๊ฐ€ํ•˜๊ธฐ ์œ„ํ•ด์„œ๋Š” ์ˆ˜์ต, ๋ฆฌ์Šคํฌ, ๋ณ€๋™์„ฑ ๋ฐ ์œ ๋™์„ฑ๊ณผ ๊ด€๋ จ๋œ ๋‹ค์–‘ํ•œ ์ฃผ์š” ์ง€ํ‘œ๋ฅผ ๋ถ„์„ํ•ฉ๋‹ˆ๋‹ค.
์ผ์ผ ์ตœ๊ณ  ๋ฐ ์ตœ์ € ์ˆ˜์ต๋ฅ ์€ ์ž ์žฌ์ ์ธ ์ด์ต๊ณผ ์†์‹ค์˜ ๊ทœ๋ชจ๋ฅผ ๋ฐ˜์˜ํ•˜๋ฉฐ, ์ƒคํ”„ ๋น„์œจ์€ ๋ฆฌ์Šคํฌ๋ฅผ ์กฐ์ •ํ•œ ์ˆ˜์ต ์„ฑ๊ณผ๋ฅผ ์ธก์ •ํ•ฉ๋‹ˆ๋‹ค. ๋ฆฌ์Šคํฌ ์ธก๋ฉด์—์„œ๋Š” ์ตœ๋Œ€ ์†์‹คํญ๊ณผ ์ˆ˜์ต ๋Œ€๋น„ ์†์‹คํญ ๋น„์œจ์„ ๋ถ„์„ํ•˜์—ฌ ๊ทน๋‹จ์ ์ธ ์†์‹ค ์‹œ๋‚˜๋ฆฌ์˜ค๋ฅผ ํŒŒ์•…ํ•ฉ๋‹ˆ๋‹ค. ์™œ๋„๋Š” ์ˆ˜์ต ๋ถ„ํฌ์™€ ์„ฑ๊ณผ์˜ ํŽธํ–ฅ ์—ฌ๋ถ€๋ฅผ ํ‰๊ฐ€ํ•˜๋Š” ๋ฐ ๋„์›€์ด ๋ฉ๋‹ˆ๋‹ค. ์‹คํ˜„ ๋ณ€๋™์„ฑ, ํ‘œ์ค€ํ™”๋œ ์‹ค์งˆ๊ฐ€๊ฒฉ๋ณ€๋™ํญ๊ณผ ๊ฐ™์€ ๋ณ€๋™์„ฑ ์ง€ํ‘œ๋Š” ๊ฐ€๊ฒฉ ๋ณ€๋™์„ ๋ณด์—ฌ์ค๋‹ˆ๋‹ค. ํ•˜๋ฐฉ ๋ฆฌ์Šคํฌ๋ฅผ ์กฐ์ •ํ•œ ์ˆ˜์ต์€ ์ž ์žฌ์ ์ธ ์†์‹ค๊ณผ ์ด์ต์— ๋Œ€ํ•œ ์ธ์‚ฌ์ดํŠธ๋ฅผ ์ œ๊ณตํ•ฉ๋‹ˆ๋‹ค. ๋งˆ์ง€๋ง‰์œผ๋กœ, ํ‰๊ท  ๊ฑฐ๋ž˜๋Œ€๊ธˆ ๋ฐ ๊ฑฐ๋ž˜๋Œ€๊ธˆ ํŽธ์ฐจ์™€ ๊ฐ™์€ ์œ ๋™์„ฑ ์ง€ํ‘œ๋Š” ํ•ด๋‹น ์ฃผ์‹์˜ ๊ฑฐ๋ž˜ ํ™œ๋ฐœ์„ฑ์„ ๋‚˜ํƒ€๋ƒ…๋‹ˆ๋‹ค.
์ด๋Ÿฌํ•œ ์ง€ํ‘œ๋ฅผ ์ข…ํ•ฉ์ ์œผ๋กœ ๋ถ„์„ํ•˜๋ฉด Johnson & Johnson์˜ ๋ฆฌ์Šคํฌ-์ˆ˜์ต ํ”„๋กœํŒŒ์ผ์— ๋Œ€ํ•œ ๋‹ค์ฐจ์›์ ์ธ ์ดํ•ด๋ฅผ ์ œ๊ณตํ•˜๋ฉฐ, ์ด๋Š” ๋ฆฌ์Šคํฌ ๊ด€๋ฆฌ ์ ์ˆ˜์˜ ํ•ต์‹ฌ ์š”์†Œ๋กœ ์ž‘์šฉํ•ฉ๋‹ˆ๋‹ค. ์ ์ˆ˜๊ฐ€ ๋†’์„์ˆ˜๋ก Johnson & Johnson์˜ ๋ฆฌ์Šคํฌ๊ฐ€ ๋‚ฎ๋‹ค๋Š” ๊ฒƒ์„ ์˜๋ฏธํ•ฉ๋‹ˆ๋‹ค.
KeyAI
๎™